Learn about Alcon’s transformation journey to unify operations, optimise data environments, and re-establish Alcon as a medical device company after the divestiture from Novartis.
From replacing the inefficient multi-vendor mix of applications to reimagining the way Alcon works, the task ahead was enormous.
Now, at the end of the two-year journey, Dr. Ken Sullivan, VP and Global Head of Clinical R&D at Alcon, will share the experience, challenges, and key principles the company followed to unify clinical operations and data management, including:
- Selecting the right technology
- Structuring cross-functional governance
- Implementation timeline and guiding principles
Ken Sullivan
VP and Global Head, Clinical R&D
Alcon
Nearly 30 years’ experience in clinical trials and statistical sciences across all phases of product development in industry, academia, and NIH settings. Currently leads Alcon’s Clinical R&D team responsible for the strategic and operational design, execution, and reporting of all Alcon clinical development activities and all global medical affairs brand plans for Alcon’s pipeline and existing marketed portfolio of products.
Kevin Liang
Senior Director, Strategy Veeva MedTech
Veeva MedTech
Kevin Liang leads clinical and medical affairs strategy for the MedTech division at Veeva. Previously, Kevin was the Chief Clinical Officer at Avania Clinical (formerly Factory CRO Group) and founder of MileStone Research Organization, both full-service CROs focused in the medical device and diagnostics industry. He holds his undergraduate and doctorate degrees in Neuroscience from the University of California, Irvine.